Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
CardioVascular and Interventional Radiology
Erschienen in:

17.11.2024 | CIRSE STANDARDS OF PRACTICE GUIDELINES

CIRSE Standards of Practice on Transjugular Intrahepatic Portosystemic Shunts

verfasst von: Pierleone Lucatelli, Antonín Krajina, Romaric Loffroy, Roberto Miraglia, Claus Christian Pieper, Stéphanie Franchi-Abella, Bianca Rocco

Erschienen in: CardioVascular and Interventional Radiology | Ausgabe 12/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Proposed in the early 1980s as a solution for managing complications of portal hypertension, the percutaneous creation of transjugular intrahepatic portosystemic shunt has consistently gained a central role. Increasingly lower complication rates have been observed thanks to improvements in both technologies and the skills of interventional radiologists.

Purpose

This document is aimed at interventional radiologists and provides best practice recommendations for transjugular intrahepatic portosystemic shunt creation, describing patient selection, intraprocedural management and follow-up, in addition to recommendations in paediatric settings.

Methods

The CIRSE Standards of Practice Committee established a writing group consisting of seven European clinicians with recognised expertise in the creation of transjugular intrahepatic portosystemic shunt. The writing group reviewed the existing literature performing a pragmatic evidence search using PubMed to select relevant publications in the English language and involving human subjects, preferably published from 2009 to 2024. The final recommendations were developed by consensus.

Results

TIPS creation has an established role in the successful management of portal hypertension and its complications. This Standards of Practice document provides up-to-date recommendations for patient selection, materials, its safe performance, and follow-up with complications management.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Krajina A, Hulek P, Fejfar T, Valek V. Quality improvement guidelines for Transjugular intrahepatic portosystemic shunt (TIPS). Cardiovasc Intervent Radiol. 2012;35(6):1295–300.PubMedPubMedCentralCrossRef
2.
3.
Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, Escorsell A, Garcia-Pagan JC, Makuch R, Patch D, Matloff DS, Bosch J. Portal hypertension collaborative group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133(2):481–8.PubMedCrossRef
4.
Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D’Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.PubMedCrossRef
5.
Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2000;31(4):864–71.PubMedCrossRef
6.
Salerno F, Guevara M, Bernardi M, Moreau R, Wong F, Angeli P, Garcia-Tsao G, Lee SS. Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int. 2010;30(7):937–47.PubMedCrossRef
7.
Gaba RC, Couture PM, Bui JT, Knuttinen MG, Walzer NM, Kallwitz ER, Berkes JL, Cotler SJ. Prognostic capability of different liver disease scoring systems for prediction of early mortality after transjugular intrahepatic portosystemic shunt creation. J Vasc Interv Radiol. 2013;24(3):411–20.PubMedCrossRef
8.
Bureau C, Métivier S, D’Amico M, Péron JM, Otal P, Garcia Pagan JC, Chabbert V, Chagneau-Derrode C, Procopet B, Rousseau H, Bosch J, Vinel JP. Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. J Hepatol. 2011;54(5):901–7.PubMedCrossRef
9.
Qi X, Jia J, Bai M, Guo X, Su C, García-Pagán JC, Han G, Fan D. Transjugular intrahepatic portosystemic shunt for acute variceal bleeding: a meta-analysis. J Clin Gastroenterol. 2015;49(6):495–505.PubMedCrossRef
10.
de Franchis R, Faculty BVI. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743–52.PubMedCrossRef
11.
Lv Y, Yang Z, Liu L, Li K, He C, Wang Z, Bai W, Guo W, Yu T, Yuan X, Zhang H, Xie H, Yao L, Wang J, Li T, Wang Q, Chen H, Wang E, Xia D, Luo B, Li X, Yuan J, Han N, Zhu Y, Niu J, Cai H, Xia J, Yin Z, Wu K, Fan D, Han G, AVB-TIPS Study Group. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(8):587–98.PubMedCrossRef
12.
García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, Abraldes JG, Nevens F, Vinel JP, Mössner J, Bosch J. Early TIPS (Transjugular intrahepatic portosystemic shunt) cooperative study group. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362(25):2370–9.PubMedCrossRef
13.
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C. Baveno VII. Faculty Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959–74.PubMedCrossRef
14.
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017;65(1):310–35.PubMedCrossRef
15.
Azoulay D, Castaing D, Majno P, Saliba F, Ichaï P, Smail A, Delvart V, Danaoui M, Samuel D, Bismuth H. Salvage transjugular intrahepatic portosystemic shunt for uncontrolled variceal bleeding in patients with decompensated cirrhosis. J Hepatol. 2001;35(5):590–7.PubMedCrossRef
16.
Vangeli M, Patch D, Burroughs AK. Salvage tips for uncontrolled variceal bleeding. J Hepatol. 2002;37(5):703–4.PubMedCrossRef
17.
Barange K, Péron JM, Imani K, Otal P, Payen JL, Rousseau H, Pascal JP, Joffre F, Vinel JP. Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology. 1999;30(5):1139–43.PubMedCrossRef
18.
Sauerbruch T, Mengel M, Dollinger M, Schepke M. Fimmers R for the German study group for the prophylaxis of variceal rebleeding. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology. 2015;149(3):660–8.PubMedCrossRef
19.
Fagiuoli S, Bruno R, Debernardi Venon W, Schepis F, Vizzutti F, Toniutto P, Senzolo M, Caraceni P, Salerno F, Angeli P, Cioni R, Vitale A, Grosso M, De Gasperi A, D’Amico G, Marzano A. AISF TIPS special conference. Consensus conference on TIPS management: techniques, indications, contraindications. Dig Liver Dis. 2017;49(2):121–37.PubMedCrossRef
20.
Holster IL, Tjwa ETTL, Moelker A, Wils A, Hansen BE, Vermeijden JR, Scholten P, van Hoek B, Nicolai JJ, Kuipers EJ, Pattynama PMT, van Buuren HR. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy + β-blocker for prevention of variceal rebleeding. Hepatology. 2016;63(2):581–9.PubMedCrossRef
21.
Zhang H, Zhang H, Li H, Zhang H, Zheng D, Sun CM, Wu J. TIPS versus endoscopic therapy for variceal rebleeding in cirrhosis: a meta-analysis update. J Huazhong Univ Sci Technolog Med Sci. 2017;37(4):475–85.PubMedCrossRef
22.
Lv Y, Qi X, He C, Wang Z, Yin Z, Niu J, Guo W, Bai W, Zhang H, Xie H, Yao L, Wang J, Li T, Wang Q, Chen H, Liu H, Wang E, Xia D, Luo B, Li X, Yuan J, Han N, Zhu Y, Xia J, Cai H, Yang Z, Wu K, Fan D, Han G, PVT-TIPS Study Group. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial. Gut. 2018;67(12):2156–68.PubMedCrossRef
23.
Lo GH, Liang HL, Chen WC, Chen MH, Lai KH, Hsu PI, Lin CK, Chan HH, Pan HB. A prospective, randomized controlled trial of transjugular intrahepatic portosystemic shunt versus cyanoacrylate injection in the prevention of gastric variceal rebleeding. Endoscopy. 2007;39(8):679–85.PubMedCrossRef
24.
Lakhoo J, Bui JT, Lokken RP, Ray CE Jr, Gaba RC. Transjugular intrahepatic portosystemic shunt creation and variceal coil or plug embolization ineffectively attain gastric variceal decompression or occlusion: results of a 26-patient retrospective study. J Vasc Interv Radiol. 2016;27(7):1001–11.PubMedCrossRef
25.
Liu J, Yang C, Huang S, Zhou C, Shi Q, Qian K, Song S, Xiong B. The combination of balloon-assisted antegrade transvenous obliteration and transjugular intrahepatic portosystemic shunt for the management of cardiofundal varices hemorrhage. Eur J Gastroenterol Hepatol. 2020;32(5):656–62.PubMedPubMedCentralCrossRef
26.
27.
Escorsell A, García-Pagán JC, Alvarado-Tapia E, Aracil C, Masnou H, Villaneuva C, Bosch J. Pre-emptive TIPS for the treatment of bleeding from gastric fundal varices: Results of a randomised controlled trial. JHEP Rep. 2023;5(6): 100717.PubMedPubMedCentralCrossRef
28.
Wang YB, Zhang JY, Gong JP, Zhang F, Zhao Y. Balloon-occluded retrograde transvenous obliteration versus transjugular intrahepatic portosystemic shunt for treatment of gastric varices due to portal hypertension: a meta-analysis. J Gastroenterol Hepatol. 2016;31(4):727–33.PubMedCrossRef
29.
García-Pagán JC, Villanueva C, Albillos A, Bañares R, Morillas R, Abraldes JG, Bosch J, Spanish Variceal Bleeding Study Group. Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial. Gut. 2009;58(8):1144–50.PubMedCrossRef
30.
Nayar M, Saravanan R, Rowlands PC, McWilliams RG, Evans J, Sutton RJ, Gilmore IT, Smart HL, Lombard MG. TIPSS in the treatment of ectopic variceal bleeding. Hepatogastroenterology. 2006;53(70):584–7.PubMed
31.
Kochar N, Tripathi D, McAvoy NC, Ireland H, Redhead DN, Hayes PC. Bleeding ectopic varices in cirrhosis: the role of transjugular intrahepatic portosystemic stent shunts. Aliment Pharmacol Ther. 2008;28(3):294–303.PubMedCrossRef
32.
Vidal V, Joly L, Perreault P, Bouchard L, Lafortune M, Pomier-Layrargues G. Usefulness of transjugular intrahepatic portosystemic shunt in the management of bleeding ectopic varices in cirrhotic patients. Cardiovasc Intervent Radiol. 2006;29(2):216–9.PubMedCrossRef
33.
Vangeli M, Patch D, Terreni N, Tibballs J, Watkinson A, Davies N, Burroughs AK. Bleeding ectopic varices–treatment with transjugular intrahepatic porto-systemic shunt (TIPS) and embolisation. J Hepatol. 2004;41(4):560–6.PubMedCrossRef
34.
Shibata D, Brophy DP, Gordon FD, Anastopoulos HT, Sentovich SM, Bleday R. Transjugular intrahepatic portosystemic shunt for treatment of bleeding ectopic varices with portal hypertension. Dis Colon Rectum. 1999;42(12):1581–5.PubMedCrossRef
35.
Oey RC, de Wit K, Moelker A, Atalik T, van Delden OM, Maleux G, Erler NS, Takkenberg RB, de Man RA, Nevens F, van Buuren HR. Variable efficacy of TIPSS in the management of ectopic variceal bleeding: a multicentre retrospective study. Aliment Pharmacol Ther. 2018;48(9):975–83.PubMedPubMedCentralCrossRef
36.
Castagna E, Cardellicchio A, Pulitanò R, Manca A, Fenoglio L. Bleeding ileal varices: a rare cause of chronic anemia in liver cirrhosis. Intern Emerg Med. 2011;6:271–3.PubMedCrossRef
37.
Ashraf P, Shah GM, Shaikh H, Manan A, Kumar M. Transjugular intrahepatic portosystemic stenting in Portal Hypertensive Gastropathy. J Coll Physicians Surg Pak. 2009;19(9):584–5.PubMed
38.
Mezawa S, Homma H, Ohta H, Masuko E, Doi T, Miyanishi K, Takada K, Kukitsu T, Sato T, Niitsu Y. Effect of transjugular intrahepatic portosystemic shunt formation on portal hypertensive gastropathy and gastric circulation. Am J Gastroenterol. 2001;96(4):1155–9.PubMedCrossRef
39.
Urata J, Yamashita Y, Tsuchigame T, Hatanaka Y, Matsukawa T, Sumi S, Matsuno Y, Takahashi M. The effects of transjugular intrahepatic portosystemic shunt on portal hypertensive gastropathy. J Gastroenterol Hepatol. 1998;13(10):1061–7.PubMedCrossRef
40.
Gjeorgjievski M, Cappell MS. Portal hypertensive gastropathy: a systematic review of the pathophysiology, clinical presentation, natural history and therapy. World J Hepatol. 2016;8(4):231–62.PubMedPubMedCentralCrossRef
41.
Hsu WH, Wang YK, Hsieh MS, Kuo FC, Wu MC, Shih HY, Wu IC, Yu FJ, Hu HM, Su YC, Wu DC. Insights into the management of gastric antral vascular ectasia (watermelon stomach). Therap Adv Gastroenterol. 2018;14(11):1756283X17747471.CrossRef
42.
Rössle M, Ochs A, Gülberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, Reiser M, Gerbes AL. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites. N Engl J Med. 2000;342(23):1701–7.PubMedCrossRef
43.
Salerno F, Merli M, Riggio O, Cazzaniga M, Valeriano V, Pozzi M, Nicolini A, Salvatori F. Randomized controlled study of TIPS versus paracentesis plus albumin in cirrhosis with severe ascites. Hepatology. 2004;40(3):629–35.PubMedCrossRef
44.
Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, Mathurin P, Otal P, Cabarrou P, Péron JM, Vinel JP. Transjugular Intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152(1):157–63.PubMedCrossRef
45.
Narahara Y, Kanazawa H, Fukuda T, Matsushita Y, Harimoto H, Kidokoro H, Katakura T, Atsukawa M, Taki Y, Kimura Y, Nakatsuka K, Sakamoto C. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol. 2011;46(1):78–85.PubMedCrossRef
46.
Maleux G, Perez-Gutierrez NA, Evrard S, Mroue A, Le Moine O, Laleman W, Nevens F. Covered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites: a retrospective cohort study. Acta Gastroenterol Belg. 2010;73(3):336–41.PubMed
47.
Tan HK, James PD, Sniderman KW, Wong F. Long-term clinical outcome of patients with cirrhosis and refractory ascites treated with transjugular intrahepatic portosystemic shunt insertion. J Gastroenterol Hepatol. 2015;30(2):389–95.PubMedCrossRef
48.
Deltenre P, Mathurin P, Dharancy S, Moreau R, Bulois P, Henrion J, Pruvot FR, Ernst O, Paris JC, Lebrec D. Transjugular intrahepatic portosystemic shunt in refractory ascites: a meta-analysis. Liver Int. 2005;25(2):349–56.PubMedCrossRef
49.
D’Amico G, Luca A, Morabito A, Miraglia R, D’Amico M. Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis. Gastroenterology. 2005;129(4):1282–93.PubMedCrossRef
50.
Albillos A, Bañares R, González M, Catalina MV, Molinero LM. A meta-analysis of Transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J Hepatol. 2005;43(6):990–6.PubMedCrossRef
51.
Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007;133(3):825–34.PubMedCrossRef
52.
Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol. 2014;20(10):2704–14.PubMedPubMedCentralCrossRef
53.
Saab S, Nieto JM, Lewis SK, Runyon BA. TIPS versus paracentesis for cirrhotic patients with refractory ascites. Cochrane Database Syst Rev. 2006;4:004889.
54.
Nicoară-Farcău O, Han G, Rudler M, Angrisani D, Monescillo A, Torres F, Casanovas G, Bosch J, Lv Y, Thabut D, Fan D, Hernández-Gea V, García-Pagán JC. Preemptive TIPS individual data metanalysis, international variceal bleeding study and Baveno cooperation study groups. Effects of early placement of Transjugular portosystemic shunts in patients with high-risk acute variceal bleeding: a meta-analysis of individual patient data. Gastroenterology. 2021;160(1):193-205.e10.PubMedCrossRef
55.
Shen NT, Schneider Y, Congly SE, Rosenblatt RE, Namn Y, Fortune BE, Jesudian A, Brown RS Jr. Cost effectiveness of early insertion of Transjugular intrahepatic portosystemic shunts for recurrent ascites. Clin Gastroenterol Hepatol. 2018;16(9):1503-1510.e3.PubMedCrossRef
56.
Piecha F, Radunski UK, Ozga AK, Steins D, Drolz A, Horvatits T, Spink C, Ittrich H, Benten D, Lohse AW, Sinning C, Kluwe J. Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival. JHEP Rep. 2019;1(2):90–8.PubMedPubMedCentralCrossRef
57.
Harrod-Kim P, Saad WE, Waldman D. Predictors of early mortality after transjugular intrahepatic portosystemic shunt creation for the treatment of refractory ascites. J Vasc Interv Radiol. 2006;17(10):1605–10.PubMedCrossRef
58.
Runyon BA, AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009;49(6):2087–107.PubMedCrossRef
59.
Gülberg V, Liss I, Bilzer M, Waggershauser T, Reiser M, Gerbes AL. Improved quality of life in patients with refractory or recidivant ascites after insertion of transjugular intrahepatic portosystemic shunts. Digestion. 2002;66(2):127–30.PubMedCrossRef
60.
Dhanasekaran R, West JK, Gonzales PC, Subramanian R, Parekh S, Spivey JR, Martin LG, Kim HS. Transjugular intrahepatic portosystemic shunt for symptomatic refractory hepatic hydrothorax in patients with cirrhosis. Am J Gastroenterol. 2010;105(3):635–41.PubMedCrossRef
61.
Gordon FD, Anastopoulos HT, Crenshaw W, Gilchrist B, McEniff N, Falchuk KR, LoCicero J 3rd, Lewis WD, Jenkins RL, Trey C. The successful treatment of symptomatic, refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt. Hepatology. 1997;25(6):1366–9.PubMedCrossRef
62.
Spencer EB, Cohen DT, Darcy MD. Safety and efficacy of transjugular intrahepatic portosystemic shunt creation for the treatment of hepatic hydrothorax. J Vasc Interv Radiol. 2002;13(4):385–90.PubMedCrossRef
63.
Wilputte JY, Goffette P, Zech F, Godoy-Gepert A, Geubel A. The outcome after transjugular intrahepatic portosystemic shunt (TIPS) for hepatic hydrothorax is closely related to liver dysfunction: a long-term study in 28 patients. Acta Gastroenterol Belg. 2007;70(1):6–10.PubMed
64.
Jeffries MA, Kazanjian S, Wilson M, Punch J, Fontana RJ. Transjugular intrahepatic portosystemic shunts and liver transplantation in patients with refractory hepatic hydrothorax. Liver Transpl Surg. 1998;4(5):416–23.PubMedCrossRef
65.
Siegerstetter V, Deibert P, Ochs A, Olschewski M, Blum HE, Rössle M. Treatment of refractory hepatic hydrothorax with transjugular intrahepatic portosystemic shunt: long-term results in 40 patients. Eur J Gastroenterol Hepatol. 2001;13(5):529–34.PubMedCrossRef
66.
Violi F, Corazza GR, Caldwell SH, Perticone F, Gatta A, Angelico M, Farcomeni A, Masotti M, Napoleone L, Vestri A, Raparelli V, Basili S, PRO-LIVER Collaborators. Portal vein thrombosis relevance on liver cirrhosis: Italian venous thrombotic events registry. Intern Emerg Med. 2016;11(8):1059–66.PubMedCrossRef
67.
Valentin N, Korrapati P, Constantino J, Young A, Weisberg I. The role of transjugular intrahepatic portosystemic shunt in the management of portal vein thrombosis: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30(10):1187–93.PubMedCrossRef
68.
Senzolo M, Riggio O, Primignani M. Italian Association for the Study of the Liver (AISF) ad hoc. vascular disorders of the liver: recommendations from the Italian association for the study of the liver (AISF) ad hoc committee. Dig Liver Dis. 2011;43(7):503–14.PubMedCrossRef
69.
Northup PG, Garcia-Pagan JC, Garcia-Tsao G, Intagliata NM, Superina RA, Roberts LN, Lisman T, Valla DC. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American association for the study of liver diseases. Hepatology. 2021;73(1):366–413.PubMedCrossRef
70.
Qi X, He C, Guo W, Yin Z, Wang J, Wang Z, Niu J, Bai M, Yang Z, Fan D, Han G. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with variceal bleeding in liver cirrhosis: outcomes and predictors in a prospective cohort study. Liver Int. 2016;36(5):667–76.PubMedCrossRef
71.
Thornburg B, Desai K, Hickey R, Hohlastos E, Kulik L, Ganger D, Baker T, Abecassis M, Caicedo JC, Ladner D, Fryer J, Riaz A, Lewandowski RJ, Salem R. Pretransplantation portal vein recanalization and Transjugular intrahepatic portosystemic shunt creation for chronic portal vein thrombosis: final analysis of a 61-patient cohort. J Vasc Interv Radiol. 2017;28(12):1714-1721.e2.PubMedCrossRef
72.
Sandri GBL, Lai Q, Lucatelli P, Melandro F, Guglielmo N, Mennini G, Berloco PB, Fanelli F, Salvatori FM, Rossi M. Transjugular intrahepatic portosystemic shunt for a wait list patient is not a contraindication for orthotopic liver transplant outcomes. Exp Clin Transplant. 2013;11(5):426–8.CrossRef
73.
Klinger C, Riecken B, Schmidt A, De Gottardi A, Meier B, Bosch J, Caca K. Transjugular local thrombolysis with/without TIPS in patients with acute non-cirrhotic, non-malignant portal vein thrombosis. Dig Liver Dis. 2017;49(12):1345–52.PubMedCrossRef
74.
Rodrigues SG, Sixt S, Abraldes JG, De Gottardi A, Klinger C, Bosch J, Baumgartner I, Berzigotti A. Systematic review with meta-analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis. Aliment Pharmacol Ther. 2019;49(1):20–30.PubMedCrossRef
75.
European Association for the Study of the Liver. EASL Clinical practice guidelines: vascular diseases of the liver. J Hepatol. 2016;64(1):179–202.CrossRef
76.
Tripathi D, Sunderraj L, Vemala V, Mehrzad H, Zia Z, Mangat K, West R, Chen F, Elias E, Olliff SP. Long-term outcomes following percutaneous hepatic vein recanalization for Budd-Chiari syndrome. Liver Int. 2017;37(1):111–20.PubMedCrossRef
77.
Mukund A, Mittal K, Mondal A, Sarin SK. Anatomic recanalization of hepatic vein and inferior vena cava versus direct intrahepatic portosystemic shunt creation in budd-chiari syndrome: overall outcome and midterm transplant-free survival. J Vasc Interv Radiol. 2018;29(6):790–9.PubMedCrossRef
78.
Valla DC. Budd-Chiari syndrome/hepatic venous outflow tract obstruction. Hepatol Int. 2018;12(Suppl 1):168–80.PubMedCrossRef
79.
Potthoff A, Attia D, Pischke S, Mederacke I, Beutel G, Rifai K, Deterding K, Heiringhoff K, Klempnauer J, Strassburg CP, Manns MP, Bahr MJ. Long-term outcome of liver transplant patients with Budd-Chiari syndrome secondary to myeloproliferative neoplasms. Liver Int. 2015;35(8):2042–9.PubMedCrossRef
80.
Khan F, Armstrong MJ, Mehrzad H, Chen F, Neil D, Brown R, Cain O, Tripathi D. Review article: a multidisciplinary approach to the diagnosis and management of Budd-Chiari syndrome. Aliment Pharmacol Ther. 2019;49(7):840–63.PubMedCrossRef
81.
De Gottardi A, Rautou PE, Schouten J, Rubbia-Brandt L, Leebeek F, Trebicka J, Murad SD, Vilgrain V, Hernandez-Gea V, Nery F, Plessier A, Berzigotti A, Bioulac-Sage P, Primignani M, Semela D, Elkrief L, Bedossa P, Valla D, Garcia-Pagan JC, VALDIG group. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol. 2019;4(5):399–411.PubMedCrossRef
82.
Schouten JNL, Garcia-Pagan JC, Valla DC, Janssen HLA. Idiopathic noncirrhotic portal hypertension. Hepatology. 2011;54(3):1071–81.PubMedCrossRef
83.
Tripathi D, Stanley AJ, Hayes PC, Travis S, Armstrong MJ, Tsochatzis EA, Rowe IA, Roslund N, Ireland H, Lomax M, Leithead JA, Mehrzad H, Aspinall RJ, McDonagh J, Patch D. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut. 2020;69(7):1173–92.PubMedCrossRef
84.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J Am Coll Cardiol. 2013;62(16):e147-239.PubMedCrossRef
85.
Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O’Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A, Toly C. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. Circulation. 2021;143(5):e35–71.PubMed
86.
Boike JR, Thornburg BG, Asrani SK, Fallon MB, Fortune BE, Izzy MJ, Verna EC, Abraldes JG, Allegretti AS, Bajaj JS, Biggins SW, Darcy MD, Farr MA, Farsad K, Garcia-Tsao G, Hall SA, Jadlowiec CC, Krowka MJ, Laberge J, Lee EW, Mulligan DC, Nadim MK, Northup PG, Salem R, Shatzel JJ, Shaw CJ, Simonetto DA, Susman J, Kolli KP, VanWagner LB, Advancing Liver Therapeutic Approaches (ALTA) Consortium. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension. Clin Gastroenterol Hepatol. 2022;20(8):1636-1662.e36.PubMedCrossRef
87.
Billey C, Billet S, Robic MA, Cognet T, Guillaume M, Vinel JP, Péron JM, Lairez O, Bureau C. A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: the toulouse algorithm. Hepatology. 2019;70(6):1928–41.PubMedCrossRef
88.
Hadi M, Walker C, Desborough M, Basile A, Tsetis D, Hunt B, Müller-Hüllsbeck S, Rand T, van Delden O, Uberoi R. CIRSE Standards of practice on peri-operative anticoagulation management during interventional radiology procedures. Cardiovasc Intervent Radiol. 2021;44(4):523–36.PubMedCrossRef
89.
Venkatesan AM, Kundu S, Sacks D, Wallace MJ, Wojak JC, Rose SC, Clark TWI, d’Othee BJ, Itkin M, Jones RS, Miller DL, Owens CA, Rajan DK, Stokes LS, Swan TL, Towbin RB, Cardella JF, Society of Interventional Radiology Standards of Practice Committee. Practice guidelines for adult antibiotic prophylaxis during vascular and interventional radiology procedures. Written by the standards of practice committee for the society of interventional radiology and endorsed by the cardiovascular interventional radiological society of Europe and canadian interventional radiology association. J Vasc Interv Radiol. 2010;21(11):1611–30.PubMedCrossRef
90.
Bureau C, Thabut D, Jezequel C, Archambeaud I, D’Alteroche L, Dharancy S, Borentain P, Oberti F, Plessier A, De Ledinghen V, Ganne-Carrié N, Carbonell N, Rousseau V, Sommet A, Péron JM, Vinel JP. The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial. Ann Intern Med. 2021;174(5):633–40.PubMedCrossRef
91.
de Wit K, Schaapman JJ, Nevens F, Verbeek J, Coenen S, Cuperus FJC, Kramer M, Tjwa ETTL, Mostafavi N, Dijkgraaf MGW, van Delden OM, Beuers UHW, Coenraad MJ, Takkenberg RB. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial). BMJ Open Gastroenterol. 2020;7(1): e000531.PubMedPubMedCentralCrossRef
92.
Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004;39(2):280–2.PubMedCrossRef
93.
Haskal ZJ, Cope C, Shlansky-Goldberg RD, Soulen MC, Baum RA, Redd DC, Pentecost MJ. Transjugular intrahepatic portosystemic shunt-related arterial injuries: prospective comparison of large- and small-gauge needle systems. J Vasc Interv Radiol. 1995;6(6):911–5.PubMedCrossRef
94.
Cannataci C, Cimo’ B, Mamone G, Tuzzolino F, D’Amico M, Cortis K, Maruzzelli L, Miraglia R. Portal vein puncture-related complications during transjugular intrahepatic portosystemic shunt creation: Colapinto needle set vs Rösch-Uchida needle set. Radiol Med. 2021;126(11):1487–95.PubMedCrossRef
95.
Zhang Y, Liu FQ, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL. Safety and efficacy of transfemoral intrahepatic portosystemic shunt for portal hypertension: a single-center retrospective study. World J Clin Cases. 2019;7(12):1410–20.PubMedPubMedCentralCrossRef
96.
Zuo K, Wang C, Wang J, Xia FF, Song T. Transjugular intrahepatic portosystemic shunt through left branch versus right branch of portal vein: a meta-analysis. Abdom Radiol (NY). 2021;46(4):1718–25.PubMedCrossRef
97.
Miraglia R, Maruzzelli L, Mamone G, Petridis I, Tuzzolino F, Luca A. Right vs left portal branch puncture in TIPS creation with controlled expansion covered stent: comparison of hemodynamic and clinical outcomes. Eur Radiol. 2023;33(4):2647–54.PubMedCrossRef
98.
Partovi S, Li X, Shwaiki O, Rashwan B, Ruff C, Grozinger G, Gadani S, Szaflarski D, Thompson D, D’Amico G, Levitin A, Kapoor B. Advanced portal venous access techniques for transjugular intrahepatic portosystemic shunt placement. BMJ Open Gastroenterol. 2021;8(1): e000815.PubMedPubMedCentralCrossRef
99.
Sun SH, Eche T, Dorczynski C, Otal P, Revel-Mouroz P, Zadro C, Partouche E, Fares N, Maulat C, Bureau C, Schwartz LH, Rousseau H, Dercle L, Mokrane FZ. Predicting death or recurrence of portal hypertension symptoms after TIPS procedures. Eur Radiol. 2022;32(5):3346–57.PubMedCrossRef
100.
Schepis F, Vizzutti F, Garcia-Tsao G, Marzocchi G, Rega L, De Maria N, Di Maira T, Gitto S, Caporali C, Colopi S, De Santis M, Arena U, Rampoldi A, Airoldi A, Cannavale A, Fanelli F, Mosconi C, Renzulli M, Agazzi R, Nani R, Quaretti P, Fiorina I, Moramarco L, Miraglia R, Luca A, Bruno R, Fagiuoli S, Golfieri R, Torricelli P, Di Benedetto F, Belli LS, Banchelli F, Laffi G, Marra F, Villa E. Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis. Clin Gastroenterol Hepatol. 2018;16(7):1153-1162.e7.PubMedCrossRef
101.
Pieper CC, Sprinkart AM, Nadal J, Hippe V, Meyer C, Schild HH, Thomas D. Postinterventional passive expansion of partially dilated transjugular intrahepatic portosystemic shunt stents. J Vasc Interv Radiol. 2015;26(3):388–94.PubMedCrossRef
102.
Pieper CC, Jansen C, Meyer C, Nadal J, Lehmann J, Schild HH, Trebicka J, Thomas D. Prospective evaluation of passive expansion of partially dilated transjugular intrahepatic portosystemic shunt stent grafts-a three-dimensional sonography study. J Vasc Interv Radiol. 2017;28(1):117–25.PubMedCrossRef
103.
Miraglia R, Maruzzelli L, Di Piazza A, Mamone G, Caruso S, Gentile G, Tuzzolino F, Floridia G, Petridis I, Volpes R, Luca A. Transjugular intrahepatic portosystemic shunt using the new gore viatorr controlled expansion endoprosthesis: prospective, single-center. Preliminary Experience Cardiovasc Intervent Radiol. 2019;42(1):78–86.PubMedCrossRef
104.
Miraglia R, Maruzzelli L, Luca A. Transjugular intrahepatic portosystemic shunt: a single-centre mid-term experience using the viatorr controlled-expansion stent. Dig Dis Sci. 2021;66(12):4565–7.PubMedCrossRef
105.
Praktiknjo M, Abu-Omar J, Chang J, Thomas D, Jansen C, Kupczyk P, Schepis F, Garcia-Pagan JC, Merli M, Meyer C, Strassburg CP, Pieper CC, Trebicka J. Controlled underdilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation. JHEP Rep. 2021;3(3): 100264.PubMedPubMedCentralCrossRef
106.
Kloster ML, Ren A, Shah KY, Alqadi MM, Bui JT, Lipnik AJ, Niemeyer MM, Ray CE, Gaba RC. High incidence of hepatic encephalopathy after viatorr controlled expansion Transjugular intrahepatic portosystemic shunt creation. Dig Dis Sci. 2021;66(11):4058–62.PubMedCrossRef
107.
Lv Y, Chen H, Luo B, Bai W, Li K, Wang Z, Xia D, Guo W, Wang Q, Li X, Yuan J, Cai H, Xia J, Yin Z, Fan D, Han G. Transjugular intrahepatic portosystemic shunt with or without gastro-oesophageal variceal embolisation for the prevention of variceal rebleeding: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2022;7(8):736–46.PubMedCrossRef
108.
Qi X, Liu L, Bai M, Chen H, Wang J, Yang Z, Han G, Fan D. Transjugular intrahepatic portosystemic shunt in combination with or without variceal embolization for the prevention of variceal rebleeding: a meta-analysis. J Gastroenterol Hepatol. 2014;29(4):688–96.PubMedCrossRef
109.
Wolter K, Praktiknjo M, Boie J, Decker G, Nadal J, Jansen C, Keller WIY, Meyer C, Trebicka J, Attenberger U, Thomas D. Glue embolization of gastroesophageal varices during Transjugular intrahepatic portosystemic shunt (TIPS) improves survival compared to coil-only embolization-a single-center retrospective study. Cardiovasc Intervent Radiol. 2021;44(8):1240–50.PubMedPubMedCentralCrossRef
110.
Reverter E, Blasi A, Abraldes JG, Martínez-Palli G, Seijo S, Turon F, Berzigotti A, Balust J, Bosch J, García-Pagán JC. Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis. Liver Int. 2014;34(1):16–25.PubMedCrossRef
111.
Ripamonti R, Ferral H, Alonzo M, Patel NH. Transjugular intrahepatic portosystemic shunt-related complications and practical solutions. Semin Intervent Radiol. 2006;23(2):165–76.PubMedPubMedCentralCrossRef
112.
Brass P, Hellmich M, Kolodziej L, Schick G, Smith AF. Ultrasound guidance versus anatomical landmarks for internal jugular vein catheterization. Cochrane Database Syst Rev. 2015;9(1):CD006962.
113.
Shaik FA, Slotwiner DJ, Gustafson GM, Dai X. Intra-procedural arrhythmia during cardiac catheterization: a systematic review of literature. World J Cardiol. 2020;12(6):269–84.PubMedPubMedCentralCrossRef
114.
Bettinger D, Schultheiss M, Boettler T, Muljono M, Thimme R, Rössle M. Procedural and shunt-related complications and mortality of the transjugular intrahepatic portosystemic shunt (TIPSS). Aliment Pharmacol Ther. 2016;44(10):1051–61.PubMedCrossRef
115.
Riggio O, Angeloni S, Salvatori FM, De Santis A, Cerini F, Farcomeni A, Attili AF, Merli M. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103(11):2738–46.PubMedCrossRef
116.
Casadaban LC, Parvinian A, Minocha J, Lakhoo J, Grant CW, Ray CE Jr, Knuttinen MG, Bui JT, Gaba RC. Clearing the confusion over hepatic encephalopathy after TIPS creation: incidence, prognostic factors, and clinical outcomes. Dig Dis Sci. 2015;60(4):1059–66.PubMedCrossRef
117.
D’Amico G, Pasta L, Morabito A, D’Amico M, Caltagirone M, Malizia G, Tinè F, Giannuoli G, Traina M, Vizzini G, Politi F, Luca A, Virdone R, Licata A, Pagliaro L. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39(10):1180–93.PubMedCrossRef
118.
Nolte W, Wiltfang J, Schindler C, Münke H, Unterberg K, Zumhasch U, Figulla HR, Werner G, Hartmann H, Ramadori G. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology. 1998;28(5):1215–25.PubMedCrossRef
119.
Berlioux P, Robic MA, Poirson H, Métivier S, Otal P, Barret C, Lopez F, Péron JM, Vinel JP, Bureau C. Pre-transjugular intrahepatic portosystemic shunts (TIPS) prediction of post-TIPS overt hepatic encephalopathy: the critical flicker frequency is more accurate than psychometric tests. Hepatology. 2014;59(2):622–9.PubMedCrossRef
120.
Nardelli S, Lattanzi B, Torrisi S, Greco F, Farcomeni A, Gioia S, Merli M, Riggio O. Sarcopenia Is risk factor for development of hepatic encephalopathy after Transjugular intrahepatic portosystemic shunt placement. Clin Gastroenterol Hepatol. 2017;15(6):934–6.PubMedCrossRef
121.
122.
Brown MA, Gueyikian S, Huffman S, Donahue L. Transjugular Intrahepatic Portosystemic Shunt Reduction Techniques.
123.
Fanelli F, Salvatori FM, Rabuffi P, Boatta E, Riggio O, Lucatelli P, Passariello R. Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft. AJR Am J Roentgenol. 2009;193(6):1696–702.PubMedCrossRef
124.
Ferral H, Gamboa P, Postoak DW, Albernaz VS, Young CR, Speeg KV, McMahan CA. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Radiology. 2004;231(1):231–6.PubMedCrossRef
125.
Lodato F, Berzigotti A, Lisotti A, Azzaroli F, Mosconi C, Giampalma E, Renzulli M, Cappelli A, Buonfiglioli F, Calvanese C, Zoli M, Golfieri R, Mazzella G. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience. Scand J Gastroenterol. 2012;47(12):1494–500.PubMedCrossRef
126.
Luca A, Angermayr B, Bertolini G, Koenig F, Vizzini G, Ploner M, Peck-Radosavljevic M, Gridelli B, Bosch J. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl. 2007;13(8):1174–80.PubMedCrossRef
127.
Luca A, Miraglia R, Maruzzelli L, D’Amico M, Tuzzolino F. Early liver failure after Transjugular intrahepatic portosystemic shunt in patients with cirrhosis with model for end-stage liver disease score of 12 or less: incidence, outcome, and prognostic factors. Radiology. 2016;280(2):622–9.PubMedCrossRef
128.
Busk TM, Bendtsen F, Poulsen JH, Clemmesen JO, Larsen FS, Goetze JP, Iversen JS, Jensen MT, Møgelvang R, Pedersen EB, Bech JN, Møller S. Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2018;314(2):G275–86.PubMedCrossRef
129.
Paul RK, Vazirani R, McDermott JC, Kliewer MA. Identification of the most important subset of doppler, laboratory, and clinical parameters for serial TIPS evaluation. AJR Am J Roentgenol. 2021;217(1):164–71.PubMedCrossRef
130.
Zizka J, Eliás P, Krajina A, Michl A, Lojík M, Ryska P, Masková J, Hůlek P, Safka V, Vanásek T, Bukac J. Value of doppler sonography in revealing transjugular intrahepatic portosystemic shunt malfunction: a 5-year experience in 216 patients. AJR Am J Roentgenol. 2000;175(1):141–8.PubMedCrossRef
131.
Carr CE, Tuite CM, Soulen MC, Shlansky-Goldberg RD, Clark TWI, Mondschein JI, Kwak A, Patel AA, Coleman BG, Trerotola SO. Role of ultrasound surveillance of transjugular intrahepatic portosystemic shunts in the covered stent era. J Vasc Interv Radiol. 2006;17(8):1297–305.PubMedCrossRef
132.
Fanelli F, Bezzi M, Bruni A, Corona M, Boatta E, Lucatelli P, Passariello R. Multidetector-row computed tomography in the evaluation of transjugular intrahepatic portosystemic shunt performed with expanded-polytetrafluoroethylene-covered stent-graft. Cardiovasc Intervent Radiol. 2011;34(1):100–5.PubMedCrossRef
133.
Büttner L, Aigner A, Pick L, Brittinger J, Steib CJ, Böning G, Streitparth F. 25 years of experience with transjugular intrahepatic portosystemic shunt (TIPS): changes in patient selection and procedural aspects. Insights Imaging. 2022;13(1):73.PubMedPubMedCentralCrossRef
134.
Hayek G, Ronot M, Plessier A, Sibert A, Abdel-Rehim M, Zappa M, Rautou PE, Valla D, Vilgrain V. Long-term outcome and analysis of dysfunction of Transjugular intrahepatic portosystemic shunt placement in chronic primary budd-chiari syndrome. Radiology. 2017;283(1):280–92.PubMedCrossRef
135.
Rowley MW, Choi M, Chen S, Hirsch K, Seetharam AB. Refractory hepatic encephalopathy after elective transjugular intrahepatic portosystemic shunt: risk factors and outcomes with revision. Cardiovasc Intervent Radiol. 2018;41(11):1765–72.PubMedCrossRef
136.
Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362(12):1071–81.PubMedCrossRef
137.
Taylor AG, Kolli KP, Kerlan RK Jr. Techniques for transjugular intrahepatic portosystemic shunt reduction and occlusion. Tech Vasc Interv Radiol. 2016;19(1):74–81.PubMedCrossRef
138.
Blue RC, Lo GC, Kim E, Patel RS, Nowakowski FS, Lookstein RA, Fischman AM. Transjugular intrahepatic portosystemic shunt flow reduction with adjustable polytetrafluoroethylene-covered balloon-expandable stents using the “sheath control” technique. Cardiovasc Intervent Radiol. 2016;39(6):935–9.PubMedCrossRef
139.
Wang Q, Lv Y, Bai M, Wang Z, Liu H, He C, Niu J, Guo W, Luo B, Yin Z, Bai W, Chen H, Wang E, Xia D, Li X, Yuan J, Han N, Cai H, Li T, Xie H, Xia J, Wang J, Zhang H, Wu K, Fan D, Han G. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding. J Hepatol. 2017;67(3):508–16.PubMedCrossRef
140.
Haskal Z, Pentecost MJ, Soulen MC, Shlansky-Goldberg RD, Baum RA, Cope C. Transjugular intrahepatic portosystemic shunt stenosis and revision: early and midterm results. AJR Am J Roentgenol. 1994;163(2):439–44.PubMedCrossRef
141.
Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, Perreault P, Péron JM, Abraldes JG, Bouchard L, Bilbao JI, Bosch J, Rousseau H, Vinel JP. Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology. 2004;126(2):469–75.PubMedCrossRef
142.
Rössle M, Siegerstetter V, Euringer W, Olschewski M, Kromeier J, Kurz K, Langer M. The use of a polytetrafluoroethylene-covered stent graft for transjugular intrahepatic portosystemic shunt (TIPS): long-term follow-up of 100 patients. Acta Radiol. 2006;47(7):660–6.PubMedCrossRef
143.
Riggio O, Ridola L, Lucidi C, Angeloni S. Emerging issues in the use of transjugular intrahepatic portosystemic shunt (TIPS) for management of portal hypertension: time to update the guidelines? Dig Liver Dis. 2010;42(7):462–7.PubMedCrossRef
144.
Jirkovsky V, Fejfar T, Safka V, Hulek P, Krajina A, Chovanec V, Raupach J, Lojik M, Vanasek T, Renc O, Ali SM. Influence of the secondary deployment of expanded polytetrafluoroethylene-covered stent grafts on maintenance of transjugular intrahepatic portosystemic shunt patency. J Vasc Interv Radiol. 2011;22(1):55–60.PubMedCrossRef
145.
Triantafyllou T, Aggarwal P, Gupta E, Svetanoff WJ, Bhirud DP, Singhal S. Polytetrafluoroethylene-covered stent graft versus bare stent in transjugular intrahepatic portosystemic shunt: systematic review and meta-analysis. J Laparoendosc Adv Surg Tech A. 2018;28(7):867–79.PubMedCrossRef
146.
Garcia-Pagán JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, Vizzini G, Abraldes JG, Olliff S, Nicolini A, Luca A, Primignani M, Janssen HLA, Valla D, Elias E, Bosch J, Budd-Chiari Syndrome-Transjugular Intrahepatic Portosystemic Shunt Group. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology. 2008;135(3):808–15.PubMedCrossRef
147.
Saugel B, Phillip V, Gaa J, Berger H, Lersch C, Schultheiss C, Thies P, Schneider H, Höllthaler J, Herrmann A, Schmid RM, Huber W. Advanced hemodynamic monitoring before and after transjugular intrahepatic portosystemic shunt: implications for selection of patients–a prospective study. Radiology. 2012;262(1):343–52.PubMedCrossRef
148.
Brand M, Prodehl L, Ede CJ. Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis. Cochrane Database Syst Rev. 2018;10(10):CD001023.PubMed
149.
Miao Z, Lu J, Yan J, Lu L, Ye B, Gu M. Comparison of therapies for secondary prophylaxis of esophageal variceal bleeding in cirrhosis: a network meta-analysis of randomized controlled trials. Clin Ther. 2020;42(7):1246-1275.e3.PubMedCrossRef
150.
Larrue H, D’Amico G, Olivas P, Lv Y, Bucsics T, Rudler M, Sauerbruch T, Hernandez-Gea V, Han G, Reiberger T, Thabut D, Vinel JP, Péron JM, García-Pagán JC, Bureau C. TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis. J Hepatol. 2023;79(3):692–703.PubMedCrossRef
151.
Boyer TD, Haskal ZJ, American Association for the Study of Liver Diseases. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension: update 2009. Hepatology. 2010;51(1):306.PubMedCrossRef
152.
European Association for the Study of the Liver (EASL). EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–60.CrossRef
153.
Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol. 2020;26(2):83–127.CrossRef
154.
Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: ascites and related complications. Clin Mol Hepatol. 2018;24(3):230–77.CrossRef
155.
Martínez-Rodrigo JJ, Boukhoubza A, Pérez Enguix D, García-Marcos R, Vila-Carbó JJ, Domenech A, Sangüesa Nebot C, Solana J, Marti-Bonmatí L. Feasibility and outcomes of transjugular intrahepatic portosystemic shunts in infants. Pediatr Radiol. 2023;53(5):953–62.PubMedCrossRef
156.
Wang Y, Ma B, Li P, Li W, Liu D. Feasibility and clinical effectiveness of transjugular intrahepatic portosystemic shunt creation in pediatric and adolescent patients: a meta-analysis. Pediatr Surg Int. 2022;38(3):377–87.PubMedCrossRef
157.
Lorenz JM. Placement of transjugular intrahepatic portosystemic shunts in children. Tech Vasc Interv Radiol. 2008;11(4):235–40.PubMedCrossRef
158.
Deshmukh A, Jhaveri A, Nagral A, Marar S. Techniques and outcomes of Transjugular intrahepatic portosystemic shunting in infants with budd-chiari syndrome. Vasc Interv Radiol. 2021;32(12):1637–43.CrossRef
159.
Deniz S, Schinner R, Monroe EJ, Horslen S, Srinivasa RN, Lv Y, Fan D, Han G, Sarma MS, Srivastava A, Poddar U, Yadav R, Hoang TPT, Lange CM, Öcal O, Ricke J, Seidensticker M, Lurz E, Di Giorgio A, D’Antiga L, Wildgruber M. Outcome of children with transjugular intrahepatic portosystemic shunt: a meta-analysis of individual patient data. Cardiovasc Intervent Radiol. 2023;46(9):1203–13.PubMedPubMedCentralCrossRef
Metadaten
Titel
CIRSE Standards of Practice on Transjugular Intrahepatic Portosystemic Shunts
verfasst von
Pierleone Lucatelli
Antonín Krajina
Romaric Loffroy
Roberto Miraglia
Claus Christian Pieper
Stéphanie Franchi-Abella
Bianca Rocco
Publikationsdatum
17.11.2024
Verlag
Springer US
Erschienen in
CardioVascular and Interventional Radiology / Ausgabe 12/2024
Print ISSN: 0174-1551
Elektronische ISSN: 1432-086X
DOI
https://doi.org/10.1007/s00270-024-03866-y

Weitere Artikel der Ausgabe 12/2024

Mid-Term Outcomes of the Iliac Branch Endoprosthesis with Standardized Combinations of Bridging Stent-Grafts for Endovascular Treatment of Aortoiliac Disease with or Without Co-existing Hypogastric Aneurysms (The HYPROTECT Study)

  • Clinical Investigation

Acute and Chronic Ilio-Femoral Venous Reconstruction

  • Review

Invited Commentary on « Cryoablation in Extra-Abdominal Desmoid Tumors: A 10-Year Experience in Pediatric and Young Adult Patients»

  • Commentary

Genicular Artery embolisation in Patients with Osteoarthritis of the Knee (GENESIS) Using Permanent Microspheres: Long-Term Results

  • Open Access
  • CLINICAL INVESTIGATION

A Novel Challenge Beyond the Pinnacle: Intravascular Ultrasound-Guided Percutaneous Deep Venous Arterialization

  • COMMENTARY

Current Evidence for Endovascular Therapies in the Management of Acute Deep Vein Thrombosis

  • Review

Neu im Fachgebiet Radiologie

KI-gestütztes Mammografiescreening überzeugt im Praxistest

Mit dem Einsatz künstlicher Intelligenz lässt sich die Detektionsrate im Mammografiescreening offenbar deutlich steigern. Mehr unnötige Zusatzuntersuchungen sind laut der Studie aus Deutschland nicht zu befürchten.

Stumme Schlaganfälle − ein häufiger Nebenbefund im Kopf-CT?

In 4% der in der Notfallambulanz initiierten zerebralen Bildgebung sind „alte“ Schlaganfälle zu erkennen. Gar nicht so selten handelt es sich laut einer aktuellen Studie dabei um unbemerkte Insulte. Bietet sich hier womöglich die Chance auf ein effektives opportunistisches Screening?

Die elektronische Patientenakte kommt: Das sollten Sie jetzt wissen

Am 15. Januar geht die „ePA für alle“ zunächst in den Modellregionen an den Start. Doch schon bald soll sie in allen Praxen zum Einsatz kommen. Was ist jetzt zu tun? Was müssen Sie wissen? Wir geben in einem FAQ Antworten auf 21 Fragen.

Stören weiße Wände und viel Licht die Bildqualitätskontrolle?

Wenn es darum geht, die technische Qualität eines Mammogramms zu beurteilen, könnten graue Wandfarbe und reduzierte Beleuchtung im Bildgebungsraum von Vorteil sein. Darauf deuten zumindest Ergebnisse einer kleinen Studie hin. 

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise